Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0973 | 0.2079 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0973 | 0.2079 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0479 | 0.1022 |
Loa Loa (eye worm) | hypothetical protein | 0.0188 | 0.4287 | 0.9159 |
Loa Loa (eye worm) | hypothetical protein | 0.0188 | 0.4287 | 0.9159 |
Loa Loa (eye worm) | hypothetical protein | 0.0203 | 0.4681 | 1 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.006 | 0.0961 | 0.2052 |
Brugia malayi | 3'5'-cyclic nucleotide phosphodiesterase family protein | 0.0203 | 0.4681 | 1 |
Onchocerca volvulus | 0.006 | 0.0961 | 0.5 | |
Loa Loa (eye worm) | calcium/calmodulin-stimulated cyclic nucleotide phosphodiesterase | 0.0203 | 0.4681 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0188 | 0.4287 | 0.9159 |
Schistosoma mansoni | camp-specific cyclic nucleotide phosphodiesterase | 0.0203 | 0.4681 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0479 | 0.1022 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0973 | 0.2079 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0973 | 0.2079 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.0479 | 0.1022 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0961 | 0.2052 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.01 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 0.5623 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.